Lilly says its experimental drug retatrutide reduced blood sugar and body weight more than injectable Ozempic 2 mg in an 80-week trial of adults with type 2 diabetes. The October 28 announcement offers a direct comparison with an established diabetes treatment, but the findings remain company-reported topline results.
Evidence level: Promising. Randomized human trial, with results disclosed by the sponsor rather than a peer-reviewed paper. As of October 29, 2026, we found no peer-reviewed TRANSCEND-T2D-2 report. Retatrutide remains investigational. This study did not establish slower aging, longer life or dementia prevention.
Featured image: AI-generated conceptual illustration of diabetes and metabolic-health research. It does not depict trial participants, a retatrutide product or experimental evidence.
What the trial tested
TRANSCEND-T2D-2, registered as NCT06260722, is a randomized, open-label Phase 3 study sponsored by Lilly. The company reports 1,298 adults whose diabetes was inadequately controlled with metformin, with or without an SGLT2 inhibitor. Participants were assigned in a 2:2:1 ratio to weekly retatrutide 9 mg, retatrutide 12 mg or injectable semaglutide 2 mg, sold as Ozempic.
The registry specifies adults aged at least 18, a body mass index of at least 25 and an A1C between 7.0% and 10.5%. A1C is a measure of blood glucose over the preceding few months. The primary question was whether 12 mg retatrutide was no worse than Ozempic for A1C change at week 80, within a prespecified noninferiority margin. Superiority was also evaluated.
Open label means participants and investigators knew which treatment was assigned. Randomization strengthens the comparison, but awareness of treatment can influence behavior and adverse-event reporting. The results apply to the studied population and treatment conditions, rather than everyone with diabetes or everyone seeking weight loss.
Retatrutide activates three hormone receptors: GIP, GLP-1 and glucagon. It began at 2 mg, with increases every four weeks toward the assigned dose, according to Lilly. Ozempic is a GLP-1 receptor agonist. This comparison concerns injectable Ozempic 2 mg for diabetes; it does not establish superiority over every semaglutide dose, brand or formulation.
The reported blood-sugar and weight results
| Measure | Retatrutide 9 mg | Retatrutide 12 mg | Ozempic 2 mg |
|---|---|---|---|
| A1C reduction, percentage points | 2.2 | 2.2 | 1.8 |
| Body-weight reduction | 19.5% | 20.9% | 9.4% |
These are reductions from baseline, not final A1C values. The average starting A1C was 8.3%. A fall of 2.2 percentage points is different from a relative reduction of 2.2%. The weight figures describe the percentage of starting body weight lost.
The statistical qualification matters. Lilly reports p<0.001 under a testing procedure controlling the family-wise false-positive rate for 12 mg A1C superiority and both weight comparisons. The 9 mg A1C superiority result was nominal p<0.001, without that correction. Its A1C noninferiority result did meet the controlled testing procedure. The release provides no confidence intervals.
What the headline analysis assumes
The efficacy figures estimate what would happen if randomized participants remained on the assigned treatment for 80 weeks without adding glucose-lowering medication for more than 14 days. Lilly calls this the efficacy estimand. It allows dose interruptions and modifications. This is a hypothetical analysis of the randomized population, rather than a simple average of everyone’s outcome after assignment.
A treatment-regimen analysis would address a different practical question: outcomes regardless of stopping the assigned drug or needing additional glucose medication. Lilly did not supply those estimates in this announcement, and the registry has no posted results. We could not verify treatment-regimen figures in the accessible primary sources reviewed. The headline numbers should therefore not be presented as the expected outcome for every person who starts treatment.
Side effects and stopping treatment
| Measure | Retatrutide 9 mg | Retatrutide 12 mg | Ozempic 2 mg |
|---|---|---|---|
| Diarrhea | 28.3% | 32.7% | 26.4% |
| Nausea | 21.2% | 23.8% | 21.3% |
| Constipation | 14.2% | 13.1% | 19.8% |
| Vomiting | 10.2% | 15.0% | 13.2% |
| Indigestion | 10.4% | 8.5% | 11.6% |
| Altered sensation (dysesthesia) | 4.8% | 6.5% | 2.7% |
| Urinary tract infection | 5.8% | 4.2% | 5.8% |
| Stopped treatment because of adverse events | 4.8% | 7.9% | 2.7% |
Gastrointestinal symptoms were common across the groups. The pattern was mixed, with more diarrhea at both retatrutide doses and more vomiting at 12 mg than with Ozempic, while constipation was less frequent. Adverse-event discontinuations were higher with either retatrutide dose, especially 12 mg. Tolerability affects whether people can continue treatment and obtain its potential benefits.
Dysesthesia means altered sensation, including touch that feels unpleasant or painful, as the National Cancer Institute explains. It should not be dismissed as a cosmetic skin effect. Lilly describes most of the listed events as mild or moderate and usually resolving during treatment, but the release lacks a full serious-adverse-event table and detailed information on persistence. Those gaps prevent a complete benefit-risk judgment.
Why this matters for healthy aging
Diabetes care matters to healthy aging because high blood glucose and related risk factors can damage blood vessels, kidneys, nerves and eyes. The National Institute of Diabetes and Digestive and Kidney Diseases explains how managing diabetes, blood pressure and cholesterol can help prevent complications. Better treatment options could therefore matter to maintaining health and function over time.
That relevance is separate from evidence that retatrutide extends life. Lilly also reports improvements in blood pressure and blood fats, but risk-factor improvements do not prove fewer heart attacks, strokes or cardiovascular deaths. This trial did not establish a longevity benefit, an effect on the rate of aging or dementia prevention.
What remains unresolved
The registry record, last updated September 28, still lists estimated enrollment of 1,250 and no posted results. That record predates Lilly’s report of 1,298 randomized adults. It confirms the design and prespecified outcomes but cannot independently validate the new numbers. No public protocol or statistical analysis plan was attached when reviewed.
Full peer review is still needed to assess missing-data handling, treatment discontinuation, rescue medication, confidence intervals and the complete safety findings. Lilly says detailed results will be presented at a future meeting and published. A company announcement is a useful disclosure, but it is not independent scrutiny of the data.
The FDA’s current information says retatrutide is not part of any FDA-approved drug. Lilly also states it has no regulatory approval anywhere. As of our October 29 check, it remains an investigational treatment, with clinical value still dependent on fuller evidence and regulatory review.
Sources and evidence notes
Lilly, October 28, 2026 announcement (complete six-page PDF): trial design, headline efficacy, statistical footnotes and selected safety findings. The appended safety summaries for Foundayo and Mounjaro concern those medicines and were not treated as retatrutide trial findings.
ClinicalTrials.gov: NCT06260722; Lilly trial listing: registration, eligibility, endpoints and trial status. FDA: concerns with unapproved GLP-1 drugs: approval status. NIDDK: preventing diabetes problems: clinical context. NCI: dysesthesia: definition.
Primary sources and targeted publication searches were checked on October 29, 2026. No peer-reviewed paper for TRANSCEND-T2D-2 was located; reports from other retatrutide trials are not substitutes. All sources used here are freely accessible. This article reports evidence and uncertainty, rather than an individual treatment recommendation.